(4-amino-2-methyl-pyrimidin-5-yl)-acetic acid ethyl ester | 220895-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (4-amino-2-methyl-pyrimidin-5-yl)-acetic acid ethyl ester
• 英文别名: (4-Amino-2-methyl-pyrimidin-5-yl)-essigsaeure-aethylester；ethyl (4-amino-2-methylpyrimidin-5-yl) acetate；Ethyl (4-amino-2-methylpyrimidin-5-yl)acetate；ethyl 2-(4-amino-2-methylpyrimidin-5-yl)acetate
• CAS: 220895-93-2
• 化学式: C₉H₁₃N₃O₂
• 分子量: 195.221
• InChiKey: NPHXDZWZTCIQIB-UHFFFAOYSA-N

物化性质

• 沸点：
  324.6±27.0 °C(Predicted)
• 密度：
  1.192±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  78.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-amino-2-methyl-pyrimidin-5-yl)-acetic acid ethyl ester 在 氢氧化钾 、 氨 、 水 、 溴 作用下， 生成 硫胺素
  参考文献：
  名称：

  Matsukawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 417,443;dtsch.Ref.S.122,125

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1,2-乙烷三羧酸三乙酯 在 氨 、 sodium ethanolate 、 溶剂黄146 、 锌 、 三氯氧磷 作用下， 生成 (4-amino-2-methyl-pyrimidin-5-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  Matsukawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 417,443;dtsch.Ref.S.122,125

  摘要：

  DOI：

文献信息

• Pyrrolotriazine inhibitors of kinases
  申请人：Bristol Myers Squibb Company

  公开号：US06982265B1

  公开（公告）日：2006-01-03

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1, PDGFR, HER-1, HER-2, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式I的化合物及其药用可接受的盐。公式I的化合物抑制了诸如VEGFR-2、FGFR-1、PDGFR、HER-1、HER-2等生长因子受体的酪氨酸激酶活性，从而使其作为抗肿瘤剂具有用途。公式I的化合物也用于治疗通过生长因子受体运作的信号转导通路相关的其他疾病。
• Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
  申请人：——

  公开号：US20030069244A1

  公开（公告）日：2003-04-10

  Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): 1 or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R 3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH 2 , preferably methyl, and X, R 1 through R 6 , and Z are as described in the specification. Advantageously the groups —ZR 4 R 5 taken together comprise an —NH-substituted aryl.

  披露了治疗与p38激酶活性相关的一种或多种疾病的方法，包括向有需要的患者施用至少一种具有以下式（I）的化合物： 1 或其药学上可接受的盐、前药或溶剂，其中R 3 为氢、甲基、全氟甲基、甲氧基、卤素、氰基或NH 2 ，优选为甲基，而X、R 1 至R 6 和Z如规范中所述。有利的是，所述基团—ZR 4 R 5 共同构成一个—NH取代的芳基。
• Oxindolylquinazoline derivatives as angiogenesis inhibitors
  申请人：Zeneca Limited

  公开号：US06294532B1

  公开（公告）日：2001-09-25

  The invention relates to compounds of formula (I) and salts thereof as further defined herein, wherein ring Z is a 6-membered heterocyclic ring containing 1 to 3 nitrogen atoms, and the use of such compounds and salts to inhibit the effects of VEGF and FGF, and in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  该发明涉及公式（I）的化合物及其盐，如本文所进一步定义的，其中环Z是含有1至3个氮原子的6元杂环环，以及利用这些化合物和盐来抑制VEGF和FGF的作用，并用于治疗包括癌症和类风湿性关节炎在内的多种疾病状态。
• METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Leftheris Katerina

  公开号：US20090227567A1

  公开（公告）日：2009-09-10

  Methods of treating one or more conditions associated with p38 kinase activity are disclosed comprising administering to a patient in need thereof at least one compound having the formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R 3 is hydrogen, methyl, perfluoromethyl, methoxy, halogen, cyano, or NH 2 , preferably methyl, and X, R 1 through R 6 , and Z are as described in the specification. Advantageously the groups -ZR 4 R 5 taken together comprise an —NH-substituted aryl.

  公开了治疗与p38激酶活性相关的一种或多种疾病的方法，包括向需要治疗的患者施用至少一种具有以下式子(I)的化合物或其药学上可接受的盐、前药或溶剂，其中R3为氢、甲基、全氟甲基、甲氧基、卤素、氰基或NH2，优选为甲基，而X、R1至R6和Z如说明书所述。优点是，-ZR4R5所组成的基团共同包含一个—NH取代的芳基。
• DE671787
  申请人：——

  公开号：——

  公开（公告）日：——